{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T16:28:57Z","timestamp":1794846537759,"version":"4.9.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-09498-7","type":"journal-article","created":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T19:38:49Z","timestamp":1752262729000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Incidence and prevalence of light chain amyloidosis in the United States in 2019\u20132021 using Optum EHR data"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1930-7913","authenticated-orcid":false,"given":"Pedro A.","family":"Laires","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shona","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Gaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendon","family":"Staruk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankita","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richa","family":"Manwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,11]]},"reference":[{"issue":"1","key":"9498_CR1","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-018-0034-3","volume":"4","author":"G Merlini","year":"2018","unstructured":"Merlini, G. et al. Systemic immunoglobulin light chain amyloidosis. Nat. Rev. Dis. Primers 4(1), 38 (2018).","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"1","key":"9498_CR2","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1001\/jama.2020.5493","volume":"324","author":"MA Gertz","year":"2020","unstructured":"Gertz, M. A. & Dispenzieri, A. Systemic amyloidosis recognition, prognosis, and therapy: A systematic review. JAMA 324(1), 79\u201389 (2020).","journal-title":"JAMA"},{"key":"9498_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2023.101040","volume":"59","author":"A Sabinot","year":"2023","unstructured":"Sabinot, A. et al. State-of-the-art review on AL amyloidosis in Western Countries: Epidemiology, health economics, risk assessment and therapeutic management of a rare disease. Blood Rev. 59, 101040 (2023).","journal-title":"Blood Rev."},{"issue":"3","key":"9498_CR4","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.mayocp.2018.08.041","volume":"94","author":"RA Kyle","year":"2019","unstructured":"Kyle, R. A. et al. Incidence of AL amyloidosis in Olmsted County, Minnesota, 1990 through 2015. Mayo Clin. Proc. 94(3), 465\u2013471 (2019).","journal-title":"Mayo Clin. Proc."},{"issue":"4","key":"9498_CR5","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1111\/ejh.13472","volume":"105","author":"A Schulman","year":"2020","unstructured":"Schulman, A. et al. Patient outcomes in light chain (AL) amyloidosis: The clock is ticking from symptoms to diagnosis. Eur. J. Haematol. 105(4), 495\u2013501 (2020).","journal-title":"Eur. J. Haematol."},{"issue":"10","key":"9498_CR6","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1182\/bloodadvances.2018016402","volume":"2","author":"TP Quock","year":"2018","unstructured":"Quock, T. P., Yan, T., Chang, E., Guthrie, S. & Broder, M. S. Epidemiology of AL amyloidosis: A real-world study using US claims data. Blood Adv. 2(10), 1046\u20131053 (2018).","journal-title":"Blood Adv."},{"issue":"5","key":"9498_CR7","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1111\/ejh.14063","volume":"111","author":"UH Mellqvist","year":"2023","unstructured":"Mellqvist, U. H. et al. Epidemiology and clinical outcomes of light-chain amyloidosis in Sweden: A nationwide population-based study. Eur. J. Haematol. 111(5), 697\u2013705 (2023).","journal-title":"Eur. J. Haematol."},{"issue":"16","key":"9498_CR8","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1056\/NEJMc1917321","volume":"382","author":"S Ravichandran","year":"2020","unstructured":"Ravichandran, S., Lachmann, H. J. & Wechalekar, A. D. Epidemiologic and survival trends in amyloidosis, 1987\u20132019. N. Engl. J. Med. 382(16), 1567\u20131568 (2020).","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"9498_CR9","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1182\/blood-2015-01-620302","volume":"126","author":"G Palladini","year":"2015","unstructured":"Palladini, G. et al. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood 126(5), 612\u2013615 (2015).","journal-title":"Blood"},{"issue":"18","key":"9498_CR10","doi-asserted-by":"publisher","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","volume":"22","author":"A Dispenzieri","year":"2004","unstructured":"Dispenzieri, A. et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis. J. Clin. Oncol. 22(18), 3751\u20133757 (2004).","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"9498_CR11","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1182\/bloodadvances.2020003782","volume":"5","author":"N Abdallah","year":"2021","unstructured":"Abdallah, N. et al. Prognostic restaging after treatment initiation in patients with AL amyloidosis. Blood Adv. 5(4), 1029\u20131036 (2021).","journal-title":"Blood Adv."},{"issue":"7","key":"9498_CR12","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.3324\/haematol.2018.205336","volume":"104","author":"T Dittrich","year":"2019","unstructured":"Dittrich, T. et al. Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmia. Haematologica 104(7), 1451\u20131459 (2019).","journal-title":"Haematologica"},{"key":"9498_CR13","unstructured":"Manitoba Center for Health Policy. Concept: Charlson Comorbidity Index [Available from: http:\/\/mchp-appserv.cpe.umanitoba.ca\/viewConcept.php?printer=Y&conceptID=1098."},{"issue":"3","key":"9498_CR14","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1182\/blood-2018-06-858951","volume":"133","author":"B Lilleness","year":"2019","unstructured":"Lilleness, B., Ruberg, F. L., Mussinelli, R., Doros, G. & Sanchorawala, V. Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis. Blood 133(3), 215\u2013223 (2019).","journal-title":"Blood"},{"issue":"4","key":"9498_CR15","doi-asserted-by":"publisher","first-page":"e165","DOI":"10.3324\/haematol.2017.178095","volume":"103","author":"R Manwani","year":"2018","unstructured":"Manwani, R. et al. Rapid hematologic responses improve outcomes in patients with very advanced (stage IIIb) cardiac immunoglobulin light chain amyloidosis. Haematologica 103(4), e165\u2013e168 (2018).","journal-title":"Haematologica"},{"issue":"1","key":"9498_CR16","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s13023-022-02414-6","volume":"17","author":"N Kumar","year":"2022","unstructured":"Kumar, N. et al. Global epidemiology of amyloid light-chain amyloidosis. Orphanet J. Rare Dis. 17(1), 278 (2022).","journal-title":"Orphanet J. Rare Dis."},{"issue":"supp_1","key":"9498_CR17","first-page":"P1813","volume":"39","author":"D Mohty","year":"2018","unstructured":"Mohty, D. et al. Incidence and prevalence of light chain amyloidosis: A population-based study. Eur. Heart J. 39(supp_1), P1813 (2018).","journal-title":"Eur. Heart J."},{"issue":"1","key":"9498_CR18","doi-asserted-by":"publisher","first-page":"15736","DOI":"10.1038\/s41598-022-18990-3","volume":"12","author":"HA Hou","year":"2022","unstructured":"Hou, H. A. et al. A population-based cohort study of the epidemiology of light-chain amyloidosis in Taiwan. Sci. Rep. 12(1), 15736 (2022).","journal-title":"Sci. Rep."},{"issue":"3","key":"9498_CR19","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1080\/13506129.2021.1898365","volume":"28","author":"M Zampieri","year":"2021","unstructured":"Zampieri, M. et al. Incidence of light chain amyloidosis in Florence metropolitan area, Italy: A population-based study. Amyloid 28(3), 211\u2013212 (2021).","journal-title":"Amyloid"},{"issue":"6","key":"9498_CR20","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1111\/bjh.16000","volume":"186","author":"B Wisniowski","year":"2019","unstructured":"Wisniowski, B. et al. The epidemiology of amyloidosis in Queensland, Australia. Br. J. Haematol. 186(6), 829\u2013836 (2019).","journal-title":"Br. J. Haematol."},{"issue":"4","key":"9498_CR21","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/bjh.12286","volume":"161","author":"JH Pinney","year":"2013","unstructured":"Pinney, J. H. et al. Systemic amyloidosis in England: An epidemiological study. Br. J. Haematol. 161(4), 525\u2013532 (2013).","journal-title":"Br. J. Haematol."},{"issue":"6","key":"9498_CR22","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1097\/CCO.0000000000000881","volume":"34","author":"G Palladini","year":"2022","unstructured":"Palladini, G. & Milani, P. Advances in the treatment of light chain amyloidosis. Curr. Opin. Oncol. 34(6), 748\u2013756 (2022).","journal-title":"Curr. Opin. Oncol."},{"issue":"8","key":"9498_CR23","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41408-021-00529-w","volume":"11","author":"A Staron","year":"2021","unstructured":"Staron, A. et al. Marked progress in AL amyloidosis survival: A 40-year longitudinal natural history study. Blood Cancer J. 11(8), 139 (2021).","journal-title":"Blood Cancer J."},{"issue":"15","key":"9498_CR24","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1182\/blood-2016-11-751628","volume":"129","author":"E Muchtar","year":"2017","unstructured":"Muchtar, E. et al. Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: Cracking the glass ceiling of early death. Blood 129(15), 2111\u20132119 (2017).","journal-title":"Blood"},{"issue":"24","key":"9498_CR25","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMra2304088","volume":"390","author":"V Sanchorawala","year":"2024","unstructured":"Sanchorawala, V. Systemic light chain amyloidosis. N. Engl. J. Med. 390(24), 2295\u20132307 (2024).","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"9498_CR26","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/ajh.26590","volume":"97","author":"SV Rajkumar","year":"2022","unstructured":"Rajkumar, S. V. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am. J. Hematol. 97(8), 1086\u20131107 (2022).","journal-title":"Am. J. Hematol."},{"issue":"1","key":"9498_CR27","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41408-023-00789-8","volume":"13","author":"G Palladini","year":"2023","unstructured":"Palladini, G. et al. The management of light chain (AL) amyloidosis in Europe: Clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018. Blood Cancer J. 13(1), 19 (2023).","journal-title":"Blood Cancer J."},{"issue":"11","key":"9498_CR28","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.3324\/haematol.2015.128025","volume":"100","author":"S Sachchithanantham","year":"2015","unstructured":"Sachchithanantham, S. et al. Clinical profile and treatment outcome of older (>75 years) patients with systemic AL amyloidosis. Haematologica 100(11), 1469\u20131476 (2015).","journal-title":"Haematologica"},{"issue":"11","key":"9498_CR29","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41408-020-00385-0","volume":"10","author":"A Staron","year":"2020","unstructured":"Staron, A., Connors, L. H., Zheng, L., Doros, G. & Sanchorawala, V. Race\/ethnicity in systemic AL amyloidosis: Perspectives on disease and outcome disparities. Blood Cancer J. 10(11), 118 (2020).","journal-title":"Blood Cancer J."},{"key":"9498_CR30","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ijcard.2022.12.048","volume":"374","author":"M Prasad","year":"2023","unstructured":"Prasad, M. et al. Evolving epidemiology of transthyretin amyloid cardiomyopathy due to increased recognition in women. Int. J. Cardiol. 374, 116\u2013119 (2023).","journal-title":"Int. J. Cardiol."},{"key":"9498_CR31","unstructured":"Centers for Disease Control and Prevention (CDC). Hypertension Cascade: Hypertension Prevalence, Treatment and Control Estimates Among US Adults Aged 18 Years and Older Applying the Criteria from the American Association of Cardiology and American Heart Association\u2019s 2017 Hypertension Guidelines\u2014NHANES 2017\u20132020. Cited 2023 May 12. Available from: https:\/\/millionhearts.hhs.gov\/data-reports\/hypertension-prevalence.html."},{"issue":"Supplement 1","key":"9498_CR32","first-page":"5595","volume":"130","author":"TP Quock","year":"2017","unstructured":"Quock, T. P., Yan, T., Chang, E., Guthrie, S. & Broder, M. S. Real-world burden of comorbidities in US patients with AL amyloidosis [abstract]. Blood 130(Supplement 1), 5595 (2017).","journal-title":"Blood"},{"issue":"34","key":"9498_CR33","doi-asserted-by":"publisher","first-page":"4319","DOI":"10.1200\/JCO.2013.50.8499","volume":"31","author":"TV Kourelis","year":"2013","unstructured":"Kourelis, T. V. et al. Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. J. Clin. Oncol. 31(34), 4319\u20134324 (2013).","journal-title":"J. Clin. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-09498-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-09498-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-09498-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T06:02:01Z","timestamp":1757224921000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-09498-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,11]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["9498"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-09498-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,11]]},"assertion":[{"value":"7 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"PAL, SF, JE, JT and RM are employees of Alexion, AstraZeneca Rare Disease, and may own stock\/have stock options in the company. AG, BS and AG are Optum\u00ae employees.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was considered not human subjects research. The data was certified as de-identified by an independent statistical expert following HIPAA statistical de-identification rules and managed according to Optum customer data use agreements.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"25149"}}